2024-09-01 - Analysis Report
##  REGN Stock Analysis:

**Company Overview:** Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company that develops and commercializes life-changing medicines for serious diseases.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** REGN: 159.56%, VOO: 89.66%
* **Outperformance:** REGN has significantly outperformed VOO by 70% (159.56 - 89.66 = 70).
* **Relative Divergence:** REGN is currently at its highest relative divergence (99.48% compared to its historical range). This suggests that REGN has been outperforming VOO consistently.

**2. Recent Price Movements:**

* **Closing Price:** $1184.69
* **5-Day Moving Average:** $1192.81
* **20-Day Moving Average:** $1158.3
* **60-Day Moving Average:** $1090.18

The stock is currently trading above all three moving averages, suggesting bullish momentum. However, the 5-day moving average is slightly below the closing price, potentially indicating a short-term pullback.

**3. Technical Indicators:**

* **RSI:** 73.51 (Overbought)
* **PPO:** -0.17
* **Delta_Previous_Relative_Divergence:** 19.29 (Positive: Short-term upward momentum)

The RSI is currently in overbought territory, suggesting the stock is overvalued and a correction might be expected. The PPO is negative, indicating downward momentum. However, the positive Delta_Previous_Relative_Divergence suggests short-term upward momentum.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-01 | 13.25 | 3.55 B$ |
| 2024-05-02 | 6.7 | 3.15 B$ |
| 2023-11-02 | 9.48 | 3.36 B$ |
| 2023-08-03 | 9.05 | 3.16 B$ |
| 2024-08-01 | 9.05 | 3.16 B$ |

The most recent earnings report for the quarter ending August 2024 showed an EPS of 13.25, exceeding analysts' expectations. The company reported strong revenue growth, reaching $3.55 billion. 

**5. Overall Analysis:**

REGN has demonstrated strong historical performance, significantly outperforming the S&P 500. The stock is currently trading above its moving averages, suggesting positive momentum. However, the RSI is in overbought territory, indicating potential for a correction. Despite the negative PPO, the positive Delta_Previous_Relative_Divergence suggests a short-term upward trend. Recent earnings have been strong, exceeding analysts' expectations. 

**6. Conclusion:**

REGN remains a strong performer with a history of outperforming the market. The current high RSI and negative PPO suggest caution, but the strong recent earnings and positive Delta_Previous_Relative_Divergence indicate potential for continued growth in the short term. Investors should monitor the stock closely for signs of a correction, but the company's solid fundamentals and strong earnings suggest that REGN remains a compelling long-term investment.
